The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner.

Tumor Suppressor Protein p53

Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
02 2022
Historique:
received: 27 05 2021
accepted: 16 12 2021
revised: 01 12 2021
pubmed: 30 1 2022
medline: 11 3 2022
entrez: 29 1 2022
Statut: ppublish

Résumé

A variety of cancer entities are driven by KRAS mutations, which remain difficult to target clinically. Survival pathways, such as resistance to cell death, may represent a promising treatment approach in KRAS mutated cancers. Based on the frequently observed genomic deletions of BCL-2-related ovarian killer (BOK) in cancer patients, we explored the function of BOK in a mutant Kras

Identifiants

DOI: 10.1038/s41388-021-02161-1 PMID: 35091677 PMC: PMC8881215
pubmed: 35091677
doi: 10.1038/s41388-021-02161-1
pii: 10.1038/s41388-021-02161-1
pmc: PMC8881215
doi:

Substances chimiques

TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1376-1382

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 211179/Z/18/Z
Pays : United Kingdom

Informations de copyright

© 2021. The Author(s).

Références

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
pubmed: 30207593
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50.
doi: 10.1038/nature13385
Janic A, Valente LJ, Wakefield MJ, Di Stefano L, Milla L, Wilcox S, et al. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat Med. 2018;24:947–53.
doi: 10.1038/s41591-018-0043-5 pubmed: 29892060
Lieschke E, Wang Z, Kelly GL, Strasser A. Discussion of some ‘knowns’ and some ‘unknowns’ about the tumour suppressor p53. J Mol Cell Biol. 2019;11:212–23.
doi: 10.1093/jmcb/mjy077 pubmed: 30496435
Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097–9.
doi: 10.1126/science.6093263 pubmed: 6093263
Ichim G, Tait SWG. A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer. 2016;16:539–48.
doi: 10.1038/nrc.2016.58 pubmed: 27364482
Cory S, Huang DCS, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22:8590–607.
doi: 10.1038/sj.onc.1207102 pubmed: 14634621
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275:967–9.
doi: 10.1126/science.275.5302.967 pubmed: 9020077
Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008;27:6398–406.
doi: 10.1038/onc.2008.307 pubmed: 18955968
Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc Natl Acad Sci USA. 1997;94:12401–6.
doi: 10.1073/pnas.94.23.12401 pubmed: 9356461 pmcid: 24966
Ke FFS, Vanyai HK, Cowan AD, Delbridge ARD, Whitehead L, Grabow S, et al. Embryogenesis and adult life in the absence of intrinsic apoptosis effectors BAX, BAK, and BOK. Cell. 2018;173:1217–.e17.
doi: 10.1016/j.cell.2018.04.036 pubmed: 29775594
Zheng JH, Grace CR, Guibao CD, McNamara DE, Llambi F, Wang Y-M, et al. Intrinsic instability of BOK enables membrane permeabilization in apoptosis. Cell Rep. 2018;23:2083–.e6.
doi: 10.1016/j.celrep.2018.04.060 pubmed: 29768206 pmcid: 6500462
Echeverry N, Bachmann D, Ke F, Strasser A, Simon HU, Kaufmann T. Intracellular localization of the BCL-2 family member BOK and functional implications. Cell Death Differ. 2013;20:785–99.
doi: 10.1038/cdd.2013.10 pubmed: 23429263 pmcid: 3647236
Llambi F, Wang Y-M, Victor B, Yang M, Schneider DM, Gingras S, et al. BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-Associated degradation. Cell. 2016;165:421–33.
doi: 10.1016/j.cell.2016.02.026 pubmed: 26949185 pmcid: 5018360
Carpio MA, Michaud M, Zhou W, Fisher JK, Walensky LD, Katz SG. BCL-2 family member BOK promotes apoptosis in response to endoplasmic reticulum stress. Proc Natl Acad Sci USA. 2015;112:7201–6.
doi: 10.1073/pnas.1421063112 pubmed: 26015568 pmcid: 4466744
Yakovlev AG, Di Giovanni S, Wang G, Liu W, Stoica B, Faden AI. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem. 2004;279:28367–74.
doi: 10.1074/jbc.M313526200 pubmed: 15102863
Zhang F, Ren L, Zhou S, Duan P, Xue J, Chen H, et al. Role of B-cell lymphoma 2 ovarian killer (BOK) in acute toxicity of human lung epithelial cells caused by cadmium chloride. Med Sci Monit Int Med J Exp Clin Res. 2019;25:5356–68.
Rabachini T, Fernandez-Marrero Y, Montani M, Loforese G, Sladky V, He Z, et al. BOK promotes chemical-induced hepatocarcinogenesis in mice. Cell Death Differ. 2018;25:708–20.
doi: 10.1038/s41418-017-0008-0 pubmed: 29229991
Srivastava R, Cao Z, Nedeva C, Naim S, Bachmann D, Rabachini T, et al. BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals. Proc Natl Acad Sci USA. 2019;116:15469–74.
doi: 10.1073/pnas.1904523116 pubmed: 31311867 pmcid: 6681708
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905.
doi: 10.1038/nature08822 pubmed: 20164920 pmcid: 2826709
Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243–8.
doi: 10.1101/gad.943001 pubmed: 11751630 pmcid: 312845
Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001;410:1111–6.
doi: 10.1038/35074129 pubmed: 11323676
Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005;65:10280–8.
doi: 10.1158/0008-5472.CAN-05-2193 pubmed: 16288016
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376:2109–21.
doi: 10.1056/NEJMoa1616288 pubmed: 28445112
Naim S, Kaufmann T. The multifaceted roles of the BCL-2 family member BOK. Front Cell Dev Biol. 2020;8:574338.
doi: 10.3389/fcell.2020.574338 pubmed: 33043006 pmcid: 7523462
Ray JE, Garcia J, Jurisicova A, Caniggia I. Mtd/Bok takes a swing: proapoptotic Mtd/Bok regulates trophoblast cell proliferation during human placental development and in preeclampsia. Cell Death Differ. 2010;17:846–59.
doi: 10.1038/cdd.2009.167 pubmed: 19942931
Moravcikova E, Krepela E, Donnenberg VS, Donnenberg AD, Benkova K, Rabachini T, et al. BOK displays cell death-independent tumor suppressor activity in non-small-cell lung carcinoma. Int J Cancer. 2017;141:2050–61.
doi: 10.1002/ijc.30906 pubmed: 28744854 pmcid: 5763244
Alenzi FQB. Links between apoptosis, proliferation and the cell cycle. Br J Biomed Sci. 2004;61:99–102.
doi: 10.1080/09674845.2004.11732652 pubmed: 15250676
Brock CK, Wallin ST, Ruiz OE, Samms KM, Mandal A, Sumner EA, et al. Stem cell proliferation is induced by apoptotic bodies from dying cells during epithelial tissue maintenance. Nat Commun. 2019;10:1044.
doi: 10.1038/s41467-019-09010-6 pubmed: 30837472 pmcid: 6400930
Ke F, Voss A, Kerr JB, O’Reilly LA, Tai L, Echeverry N, et al. BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice. Cell Death Differ. 2012;19:915–25.
doi: 10.1038/cdd.2011.210 pubmed: 22281706 pmcid: 3354060
Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000;14:994–1004.
doi: 10.1101/gad.14.8.994 pubmed: 10783170 pmcid: 316543
Munkhbaatar E, Dietzen M, Agrawal D, Anton M, Jesinghaus M, Boxberg M, et al. MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nat Commun. 2020;11:4527.
doi: 10.1038/s41467-020-18372-1 pubmed: 32913197 pmcid: 7484793
Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O’Connor L, Milla L, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10:1422–32.
doi: 10.1016/j.celrep.2015.02.002 pubmed: 25732831

Auteurs

Anna-Lena Meinhardt (AL)

Department of Medicine III, Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich, Munich, Germany.
Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.

Enkhtsetseg Munkhbaatar (E)

Department of Medicine III, Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich, Munich, Germany.
Department of Surgery, School of Medicine, Technical University Munich, Munich, Germany.

Ulrike Höckendorf (U)

Department of Medicine III, Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich, Munich, Germany.
ORCID: 0000-0002-8218-3343

Michelle Dietzen (M)

Cancer Research UK Lung Cancer Center of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London, UK.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
ORCID: 0000-0002-6853-7563

Marta Dechant (M)

Department of Medicine III, Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich, Munich, Germany.

Martina Anton (M)

Institute of Molecular Immunology and Experimental Oncology, School of Medicine, Technical University of Munich, Munich, Germany.
ORCID: 0000-0001-5290-5213

Anne Jacob (A)

Institute of Pathology, Technical University of Munich, Munich, Germany.

Katja Steiger (K)

Institute of Pathology, Technical University of Munich, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
ORCID: 0000-0002-7269-5433

Wilko Weichert (W)

Institute of Pathology, Technical University of Munich, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.

Luka Brcic (L)

Diagnostic and Research Institute of Pathology, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
ORCID: 0000-0002-9098-8416

Nicholas McGranahan (N)

Cancer Research UK Lung Cancer Center of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London, UK.
ORCID: 0000-0001-9537-4045

Caterina Branca (C)

Department of Medicine III, Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich, Munich, Germany.
ORCID: 0000-0001-6231-2040

Thomas Kaufmann (T)

Institute of Pharmacology, University of Bern, Bern, Switzerland.
ORCID: 0000-0001-9906-874X

Michael A Dengler (MA)

Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria. michael.dengler@medunigraz.at.
ORCID: 0000-0002-1693-1761

Philipp J Jost (PJ)

Department of Medicine III, Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich, Munich, Germany. philipp.jost@medunigraz.at.
German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. philipp.jost@medunigraz.at.
Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria. philipp.jost@medunigraz.at.
ORCID: 0000-0003-2454-0362

Articles similaires

Patient iPSC-derived neural progenitor cells display aberrant cell cycle control, p53, and DNA damage response protein expression in schizophrenia.

Aaron Stahl, Johanna Heider, Richard Wüst et al.
1.00
Humans Induced Pluripotent Stem Cells Schizophrenia Neural Stem Cells DNA Damage

Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment.

Christina Sternberg, Martin Raigel, Tanja Limberger et al.
1.00
Male STAT3 Transcription Factor Prostatic Neoplasms Animals Mice

Caspase-2 kills cells with extra centrosomes.

Dario Rizzotto, Vincenza Vigorito, Patricia Rieder et al.
1.00
Caspase 2 Centrosome Humans BH3 Interacting Domain Death Agonist Protein Apoptosis

Loss of myosin light chain kinase induces the cellular senescence associated secretory phenotype to promote breast epithelial cell migration.

Dayoung Kim, Jonathan A Cooper, David M Helfman
1.00
Humans Myosin-Light-Chain Kinase Cell Movement Epithelial Cells Female

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › The BCL-2 family member BOK promotes...